Core Insights - Intelligent Bio Solutions Inc. reported record quarterly revenue of $1.11 million, marking a 32% increase sequentially and a 28% increase year-over-year, primarily driven by consumable cartridge sales and customer base expansion [1][2][3] Financial Performance - The fiscal 2026 first quarter revenue reached $1,111,797, up 32% from the previous quarter and 28% from the same quarter last year [7] - Cartridge sales accounted for approximately 57.59% of total revenue, increasing from 51.1% in the prior year, indicating a strong recurring revenue model [7] - Gross profit margins improved by 690 basis points year-over-year to 46.6%, attributed to enhanced operational efficiency and a favorable product mix [2][7] Operational Highlights - The company added 33 new customer accounts during the quarter, bringing the total to 492 across more than 24 countries [7] - A significant contract was secured with a London public transport operator, covering 14 operational sites and over 4,400 staff, representing a major scale deployment [7] - The product portfolio was expanded with the introduction of the SmarTest® Patch, a continuous drug monitoring solution [7] Strategic Market Expansion - The company is focusing on strategic partnerships and international market expansion, positioning itself for continued growth [2][6] - A global distribution agreement was established with SMARTOX® to introduce the SmarTest Patch technology to markets outside the U.S. and Canada [7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 Intelligent Bio Solutions Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 ...

Financial Results - Intelligent Bio Solutions Inc. announced preliminary, unaudited revenue results for the fiscal first quarter ended September 30, 2025[3]. - The press release detailing the financial results was issued on November 4, 2025[3]. Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[2].

Core Insights - Intelligent Bio Solutions Inc. achieved a record revenue of over $1 million for the fiscal first quarter ended September 30, 2025, marking a significant milestone for the company [2] - The company reported a revenue increase of approximately 32% sequentially and 28% year-over-year, indicating strong growth momentum [2][3] - Cartridge revenue rose approximately 43% year-over-year, while reader revenue increased by about 23% year-over-year, reflecting the effectiveness of the company's business model [2] Revenue Performance - The company has experienced three consecutive quarters of revenue growth, showcasing the strength of its razor-razorblade business model [2] - The anticipated revenue growth is attributed to an improved sales mix, with higher-margin consumables making up a larger share of total revenue [2] Company Overview - Intelligent Bio Solutions Inc. specializes in intelligent, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [4] - The technology is designed for quick sample collection and results, making it suitable for safety-critical industries such as construction, manufacturing, and transport [4]

Core Insights - Intelligent Bio Solutions Inc. reported a 50% increase in new customer accounts during the fiscal first quarter, totaling over 480 active accounts, indicating strong customer expansion and revenue momentum [1][3][4] Company Performance - The company added 33 new customer accounts in the fiscal first quarter ended September 30, 2025, compared to the same period last year [1] - Approximately 91% of new accounts were first-time adopters of the drug screening solution, while 9% were expansions within existing customer organizations [3] - The company aims to convert current momentum into sustained revenue growth and long-term value [3] Market Trends - The global drug screening market is projected to reach USD 17.1 billion by 2029, growing at a CAGR of 15%, driven by increasing regulatory focus on workplace safety and demand for non-invasive testing solutions [4] - Adoption of the Intelligent Fingerprinting Drug Screening System is broadening across various industries, reflecting its scalability and alignment with modern compliance standards [5] Sector Growth - Strongest growth in customer acquisition was noted in sectors such as maritime, transportation and logistics, electrical and electronic manufacturing, construction, and government administration [2] - Government administration is a newly entered sector, highlighting the expanding applicability of the company's solutions [2]

Core Insights - Intelligent Bio Solutions Inc. has secured a significant contract with a major industrial service provider in the UK, marking a key milestone in the adoption of its rapid, non-invasive drug testing technology [1][3][5] Company Overview - Intelligent Bio Solutions Inc. is a medical technology company specializing in intelligent, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [7] - The company employs approximately 3,000 staff in the UK and Ireland, with over 30,000 employees globally [1][2] Technology Adoption - The new customer account represents one of the most significant commercial deployments for INBS in the UK, aimed at modernizing workforce safety and compliance [3] - The transition from traditional urine collection methods to INBS's technology is expected to enhance testing efficiency, reduce downtime, and improve productivity [3][4] Market Confidence and Growth - The contract highlights growing market confidence in INBS's technology, which is increasingly being adopted by large industrial operators [5] - INBS's drug testing technology is currently utilized by over 480 accounts across 24 countries, supported by 18 distribution partners [6] Business Model and Revenue Potential - The company's business model is characterized by a "razor–razor-blade" approach, focusing on long-term recurring cartridge sales and sustained revenue growth [5] - The recent contract reflects INBS's continued momentum following multiple deployments in various sectors, including transportation, construction, and mining [5]

Core Insights - Intelligent Bio Solutions Inc. (INBS) is progressing towards FDA 510(k) clearance for its Intelligent Fingerprinting Drug Screening System, specifically for opiate codeine, with an anticipated timeline for clearance in the second half of 2026 [2][3] - The company is initiating clinical studies to gather additional data to support its 510(k) submission, with studies expected to conclude in the first half of 2026 [3][4] - INBS's drug testing technology has been adopted by over 450 accounts across 24 countries, indicating a strong global presence and demand for its solutions [4] Company Overview - Intelligent Bio Solutions Inc. specializes in intelligent, rapid, non-invasive testing solutions, aiming to revolutionize portable testing through fingerprint sweat analysis [5] - The Intelligent Fingerprinting Drug Screening System screens for recent drug use, including opiates, cocaine, methamphetamine, and cannabis, providing results in under ten minutes [5] - Current customer segments outside the U.S. include construction, manufacturing, engineering, transport, logistics, mining, drug treatment organizations, and coroners [5]

Core Viewpoint - Intelligent Bio Solutions Inc. is progressing through the FDA 510(k) clearance process for its Intelligent Fingerprinting Drug Screening System, which is a novel non-invasive testing solution [1][2][3]. FDA Clearance Process - The company submitted its 510(k) premarket notification to the FDA in December 2024, and received an Additional Information request in February 2025, which included over 70 items to address [2]. - INBS responded to the FDA's questions and submitted additional information in August 2025, but the FDA has requested further information, necessitating a resubmission of the 510(k) notification [3][4]. - The device is unique as there are no comparable sweat-based products currently on the market, requiring extensive validation to demonstrate its performance [3]. Company Strategy and Market Position - The company is consulting with specialized FDA consultants to evaluate the FDA's questions and plans to provide an investor update within ten days regarding the timeline for FDA clearance [4]. - The CEO expressed confidence in the technology and emphasized the company's commitment to bringing the solution to the U.S. market while continuing to grow its international business [5]. - INBS is developing partnerships and driving sales growth outside the U.S., targeting sectors such as construction, manufacturing, transport, and drug treatment organizations [6]. Product Overview - The Intelligent Fingerprinting Drug Screening System is designed for rapid, non-invasive drug testing through fingerprint sweat analysis, screening for drugs commonly found in workplaces [6]. - The system offers quick sample collection and results in under ten minutes, making it a valuable tool for safety-critical industries [6].

Core Insights - Intelligent Bio Solutions Inc. achieved record monthly cartridge sales in July 2025, with 519 boxes shipped, translating to over 12,500 cartridges and a 60% year-on-year growth [1][2]. Group 1: Business Model and Revenue Growth - Cartridges are a high-margin consumable in the Company's fingerprint sweat-based drug testing system, forming the basis of its razor/razor blade business model, which is experiencing growth due to new large contracts and an expanding global installed base [2][3]. - The Company secured a significant multi-site, high-volume contract in the transportation sector, which has increased ongoing demand for consumables [2]. - There is a growing pipeline of opportunities, with an increasing number of bids and tenders for large-scale deployments, indicating a robust demand for the Company's products [2]. Group 2: Management Insights - The President and CEO of Intelligent Bio Solutions highlighted that the record cartridge sales reflect the strength of the business model and the momentum from major contract wins, suggesting continued growth in cartridge demand and reliable revenue streams [3]. - The Company aims to leverage its installed base to drive recurring sales of cartridges while planning for U.S. market expansion beyond forensic use in the second half of 2025 [3]. Group 3: Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on intelligent, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System, which analyzes fingerprint sweat [4]. - The technology is designed to be hygienic and cost-effective, screening for drugs commonly found in the workplace, with quick sample collection and results [4]. - Current customer segments outside the U.S. include construction, manufacturing, transport, mining, and drug treatment organizations, indicating a diverse market presence [4].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 Intelligent Bio Solutions Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of i ...